MERCK GIVES UP SINEMET IN U.S. TO SHARE RIGHTS TO DuPONT's ANGIOTENSIN II BLOCKERS IN EARLY CLINICALS; MERCK WILL LEAD RESEARCH COLLABORATION

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".